



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/890,875	08/07/2001	Hiromu Ohnogi	OHNOGI=1	9130	
1444	7590 01/04/2006		EXAM	EXAMINER	
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW			HUI, SAN	HUI, SAN MING R	
SUITE 300	DIREEI, NW		ART UNIT	PAPER NUMBER	
WASHINGT	ON, DC 20001-5303		1617	,	
			DATE MAILED: 01/04/2000	5	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/890,875	OHNOGI ET AL.					
Office Action Summary	Examiner	Art Unit					
	San-ming Hui	1617					
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with t	he correspondence address					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAT 136(a). In no event, however, may a reply will apply and will expire SIX (6) MONTHS e, cause the application to become ABAND	FION. be timely filed from the mailing date of this communication. FONED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 29 M	March 2005	·					
· · · · · · · · · · · · · · · · · · ·	s action is non-final.						
3) Since this application is in condition for allowa		prosecution as to the merits is					
closed in accordance with the practice under	·	•					
Disposition of Claims							
4)⊠ Claim(s) <u>6 and 8-10</u> is/are pending in the appl	lication						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.	With thom botton delication.						
6)⊠ Claim(s) <u>6 and 8-10</u> is/are rejected.							
7) Claim(s) is/are objected to.	•						
8) Claim(s) are subject to restriction and/o	or election requirement						
Application Papers	or diconomination.						
9) The specification is objected to by the Examine		. <u>-</u>					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the	· ·						
Replacement drawing sheet(s) including the correct							
11) The oath or declaration is objected to by the E	xaminer. Note the attached Oi	tice Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	n priority under 35 U.S.C. § 11	9(a)-(d) or (f).					
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority document	ts have been received in Appli	cation No					
Copies of the certified copies of the prior	rity documents have been rec	eived in this National Stage					
application from the International Burea	u (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not rec	eived.					
Attachment(s)							
Notice of References Cited (PTO-892)	4) Interview Summ	nary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		ail Date nal Patent Application (PTO-152)					
 Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	6) Other:	Tai i atent Application (FTO-192)					

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 29, 2005 has been entered.

The outstanding rejections are withdrawn in view of the amendments filed February 22, 2005. Claims 6 and 8-10 are pending.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 9-10 are rejected under 35 U.S.C. 102(b) as being anticipated by Koyama et al. (EP 0984 001 A1 from IDS received November 7, 2001), essentially the reason of record.

Koyama et al. teaches a method of combating bacterial infections, both caused by Gram negative or positive bacteria, by employing 20mg/kg of the compounds of formula (V) (See page 11-12, paragraph [058]-[065], also in claim 26-27). Koyama et

Application/Control Number: 09/890,875

Art Unit: 1617

al. also teaches the compound of Formula (V) as administered as food product (See page 11, paragraph [059]). Koyama et al. teaches the compounds of formula (V) as useful in treating bacterial topical conditions such as bacterial atopic dermatitis (see page 12, paragraph [064]).

Therefore, the method of treating patients suffered with wound would be inherently present in the teachings of Koyama et al.

Claims 6 and 8-10 are rejected under 35 U.S.C. 102(b) as being anticipated by EP 1 050 525 ('525), received from IDS filed November 7, 2001.

'525 teaches a method of employing compounds of formula (VII) to induce human insulin-like growth factor (See claim 13).

Response to Arguments

Applicant's arguments with respect to claims 6 and 8-10 have been considered but are most in view of the new ground(s) of rejection.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

San-ming Hui

Primary Examinér Art Unit 1617